Item 1. Financial Statements
ITEM 1. FINANCIAL STATEMENTS
INGEVITY CORPORATION
Condensed Consolidated Statements of Operations (Unaudited)
Three Months Ended March 31,
In millions, except per share data 2025 2024
Net sales $ 284.0 $ 340.1
Cost of sales 170.6 240.4
Gross profit 113.4 99.7
Selling, general, and administrative expenses 43.1 47.2
Research and technical expenses 7.7 6.8
Restructuring and other (income) charges, net 12.3 62.8
Acquisition-related costs — 0.3
Other (income) expense, net 4.1 32.2
Interest expense, net 19.4 22.3
Income (loss) before income taxes 26.8 ( 71.9 )
Provision (benefit) for income taxes 6.3 ( 15.9 )
Net income (loss) $ 20.5 $ ( 56.0 )
Per share data
Basic earnings (loss) per share $ 0.56 $ ( 1.54 )
Diluted earnings (loss) per share 0.56 ( 1.54 )
The accompanying notes are an integral part of these financial statements.
3
INGEVITY CORPORATION
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)
Three Months Ended March 31,
In millions 2025 2024
Net income (loss) $ 20.5 $ ( 56.0 )
Other comprehensive income (loss), net of tax:
Foreign currency adjustments:
Foreign currency translation adjustment 17.2 ( 9.1 )
Total foreign currency adjustments, net of tax provision (benefit) of zero for all periods
17.2 ( 9.1 )
Derivative instruments:
Unrealized gain (loss), net of tax provision (benefit) of zero and $( 0.1 )
0.1 ( 0.3 )
Reclassifications of deferred derivative instruments (gain) loss, included in net income (loss), net of tax (provision) benefit of $ 0.1 and $ 0.2
0.1 0.5
Total derivative instruments, net of tax provision (benefit) of $ 0.1 and $ 0.1
0.2 0.2
Other comprehensive income (loss), net of tax provision (benefit) of $ 0.1 and $ 0.1
17.4 ( 8.9 )
Comprehensive income (loss) $ 37.9 $ ( 64.9 )
The accompanying notes are an integral part of these financial statements.
4
INGEVITY CORPORATION
Condensed Consolidated Balance Sheets
In millions, except share and par value data March 31, 2025 December 31, 2024
Assets (Unaudited)
Cash and cash equivalents $ 71.5 $ 68.0
Accounts receivable , net of allowance of $ 0.9 - 2025 and $ 0.6 - 2024
163.7 141.0
Inventories, net 245.4 226.8
Prepaid and other current assets 49.4 57.4
Current assets 530.0 493.2
Property, plant, and equipment, net 655.8 658.9
Operating lease assets, net 45.9 50.4
Goodwill 180.7 175.2
Other intangibles, net 276.8 278.8
Deferred income taxes 119.7 117.9
Restricted investment , net of allowance of $ 0.1 - 2025 and $ 0.2 - 2024
82.4 81.6
Strategic investments 87.2 87.3
Other assets 77.6 79.3
Total Assets $ 2,056.1 $ 2,022.6
Liabilities
Accounts payable $ 108.3 $ 94.5
Accrued expenses 57.2 58.1
Accrued payroll and employee benefits 18.7 27.7
Current operating lease liabilities 15.8 16.9
Notes payable and current maturities of long-term debt 60.4 61.3
Income taxes payable 4.2 5.6
Current liabilities 264.6 264.1
Long-term debt including finance lease obligations 1,332.6 1,339.7
Noncurrent operating lease liabilities 33.3 36.8
Deferred income taxes 59.0 56.2
Other liabilities 132.0 130.6
Total Liabilities 1,821.5 1,827.4
Commitments and contingencies (Note 13)
Equity
Preferred stock (par value $ 0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at 2025 and 2024, respectively)
— —
Common stock (par value $ 0.01 per share; 300,000,000 shares authorized; 43,784,531 and 43,630,211 issued and 36,450,282 and 36,350,425 outstanding at 2025 and 2024, respectively)
0.4 0.4
Additional paid-in capital 180.9 176.8
Retained earnings 592.5 572.0
Accumulated other comprehensive income (loss) ( 24.0 ) ( 41.4 )
Treasury stock, common stock, at cost ( 7,334,249 shares - 2025 and 7,279,786 shares - 2024)
( 515.2 ) ( 512.6 )
Total Equity 234.6 195.2
Total Liabilities and Equity $ 2,056.1 $ 2,022.6
The accompanying notes are an integral part of these financial statements.
5
INGEVITY CORPORATION
Condensed Consolidated Statements of Cash Flows (Unaudited)
Three Months Ended March 31,
In millions 2025 2024
Cash provided by (used in) operating activities:
Net income (loss) $ 20.5 $ ( 56.0 )
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:
Depreciation and amortization 24.9 29.6
Non cash operating lease costs 4.3 4.9
Deferred income taxes ( 0.9 ) ( 18.4 )
Restructuring and other (income) charges, net 12.3 62.8
CTO resales — 26.5
Share-based compensation 4.1 4.3
(Gain) loss on strategic investment — 4.8
Other non-cash items 0.1 7.4
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net ( 21.3 ) ( 10.2 )
Inventories, net ( 13.2 ) ( 22.7 )
Prepaid and other current assets 0.2 —
Accounts payable 8.0 ( 3.8 )
Accrued expenses 1.6 ( 2.4 )
Accrued payroll and employee benefits ( 9.1 ) ( 3.2 )
Income taxes 3.1 ( 0.8 )
Restructuring and other cash outflow, net ( 11.6 ) ( 10.0 )
Operating leases ( 5.3 ) ( 5.7 )
CTO resales cash inflow (outflow), net 6.2 ( 19.8 )
Changes in other operating assets and liabilities, net 1.5 0.6
Net cash provided by (used in) operating activities $ 25.4 $ ( 12.1 )
Cash provided by (used in) investing activities:
Capital expenditures $ ( 10.0 ) $ ( 16.6 )
Proceeds from disposition of assets 3.6 —
Other investing activities, net ( 5.1 ) 0.3
Net cash provided by (used in) investing activities $ ( 11.5 ) $ ( 16.3 )
Cash provided by (used in) financing activities:
Proceeds from revolving credit facility and other borrowings $ 92.3 $ 81.4
Payments on revolving credit facility and other borrowings ( 100.3 ) ( 55.0 )
Finance lease obligations, net ( 0.4 ) ( 0.4 )
Tax payments related to withholdings on vested equity awards ( 2.6 ) ( 2.6 )
Net cash provided by (used in) financing activities $ ( 11.0 ) $ 23.4
Increase (decrease) in cash, cash equivalents, and restricted cash 2.9 ( 5.0 )
Effect of exchange rate changes on cash 1.4 ( 1.8 )
Change in cash, cash equivalents, and restricted cash 4.3 ( 6.8 )
Cash, cash equivalents, and restricted cash at beginning of period 86.6 111.9
Cash, cash equivalents, and restricted cash at end of period (1)
$ 90.9 $ 105.1
(1) Includes restricted cash of $ 19.4 million and $ 16.6 million and cash and cash equivalents of $ 71.5 million and $ 88.5 million at March 31, 2025 and 2024, respectively. Restricted cash is included within "Prepaid and other current assets" and "Restricted investment" within the condensed consolidated balance sheets.
Supplemental cash flow information:
Cash paid for interest, net of capitalized interest $ 14.6 $ 17.0
Cash paid for income taxes, net of refunds 4.4 2.9
Purchases of property, plant, and equipment in accounts payable 2.9 2.7
Leased assets obtained in exchange for new operating lease liabilities — 0.4
The accompanying notes are an integral part of these financial statements.
6
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 1: Background
Description of Business
Ingevity Corporation ("Ingevity," "the company," "we," "us," or "our") provides products and technologies that purify, protect, and enhance the world around us. Through a diverse team of talented and experienced people, we develop, manufacture, and bring to market solutions that are largely renewably sourced and help customers solve complex problems while making the world more sustainable. Our products are used in a variety of demanding applications, including adhesives, agrochemicals, asphalt paving, bioplastics, coatings, elastomers, lubricants, paint for road markings, oil drilling, and automotive components. We operate in three reportable segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.
Basis of Consolidation and Presentation
These unaudited Condensed Consolidated Financial Statements reflect the consolidated operations of the company and have been prepared in accordance with United States Securities and Exchange Commission ("SEC") interim reporting requirements. Accordingly, the accompanying Condensed Consolidated Financial Statements do not include all disclosures required by accounting principles generally accepted in the United States of America ("GAAP") for full financial statements and should be read in conjunction with the Annual Consolidated Financial Statements for the years ended December 31, 2024, 2023 and 2022, collectively referred to as the “Annual Consolidated Financial Statements,” included in our Annual Report on Form 10-K for the year ended December 31, 2024 (the "2024 Annual Report").
In the opinion of management, the Condensed Consolidated Financial Statements contain all adjustments which include only normal recurring adjustments necessary to fairly present the financial position, results of operations, and cash flows for the interim periods presented and contain adequate disclosures to make the information presented not misleading. The consolidated results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.
The preparation of the Condensed Consolidated Financial Statements requires management to make estimates and assumptions with respect to the reported amounts of assets, liabilities, revenue, and expenses and the disclosure of contingent assets and liabilities. Actual results could differ from these estimates.
Certain prior year amounts have been reclassified to conform with the current year's presentation.
Note 2: New Accounting Guidance
The Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC" or "Codification") is the sole source of authoritative GAAP other than SEC issued rules and regulations that apply only to SEC registrants. The FASB issues an Accounting Standards Update ("ASU") to communicate changes to the Codification. We consider the applicability and impact of all ASUs. Recently issued ASUs that are not listed within this Form 10-Q have been assessed and determined to be either not applicable or are not expected to have a material impact on the Condensed Consolidated Financial Statements.
Recently Issued Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures,” which is intended to enhance income tax disclosures around the rate reconciliation and income taxes paid. The purpose of the amendment is to provide readers of the financial statements with information to better assess the differences between the effective tax rate and the statutory tax rate across multiple jurisdictions, enabling them to understand tax implications around operational opportunities and potential future cash flows. The guidance is effective beginning with our 2025 fiscal year Form 10-K and will be applied to all prior periods presented in the financial statements.
In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statement Expenses,” which is intended to enhance disclosures regarding significant expenses. The purpose of the amendment is to provide readers of the financial statements with information to better understand an entity’s overall performance, assess potential future cash flows, and compare an entity's performance over time and with that of other entities. The guidance is effective beginning with our
7
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
2027 fiscal year Form 10-K. We are currently evaluating the potential impact of adopting this new guidance on our Condensed Consolidated Financial Statements and related disclosures.
Note 3: Net Sales
Disaggregation of Net Sales
The following table presents our Net sales disaggregated by reportable segment and product line.
Three Months Ended March 31,
In millions 2025 2024
Performance Materials segment $ 146.8 $ 145.1
Road Technologies product line 44.3 45.7
Industrial Specialties product line (1)
50.7 101.3
Performance Chemicals segment $ 95.0 $ 147.0
Advanced Polymer Technologies segment $ 42.2 $ 48.0
Net sales $ 284.0 $ 340.1
_______________
(1) The reduction in the industrial specialties product line from 2024 to 2025 was due to the repositioning action taken to improve the Performance Chemicals reportable segment, refer to Note 11 for more information.
The following table presents our Net sales disaggregated by geography, based on the delivery address of our customer.
Three Months Ended March 31,
In millions 2025 2024
North America (1)
$ 158.2 $ 202.7
Asia Pacific (1)
72.3 78.4
Europe, Middle East, and Africa 43.6 48.3
South America 9.9 10.7
Net sales $ 284.0 $ 340.1
_______________
(1) Countries with Net sales in excess of 10 percent of consolidated Net sales for the three months ended March 31, 2025, and 2024 are the U.S., which totaled $ 140.3 million and $ 183.8 million, respectively, and China, which totaled $ 35.3 million and $ 42.2 million, respectively.
Contract Balances
The contract assets primarily relate to our rights to consideration for products produced but not billed at the reporting date. The contract assets are recognized as accounts receivables when we have an enforceable right to payment for performance completed to date and the customer has been billed. Contract liabilities represent obligations to transfer goods to a customer for which we have received consideration from our customer. For all periods presented, we had no contract liabilities.
8
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
The following table provides information about contract assets from contracts with certain customers.
Contract Asset
March 31,
In millions 2025 2024
Beginning balance $ 6.5 $ 11.2
Contract asset additions 1.9 8.8
Reclassification to accounts receivable, billed to customers ( 1.1 ) ( 4.1 )
Ending balance (1)
$ 7.3 $ 15.9
______________
(1) Included within "Prepaid and other current assets" on the condensed consolidated balance sheets.
Note 4: Fair Value Measurements
Recurring Fair Value Measurements
The following information is presented for assets and liabilities that are recorded on the condensed consolidated balance sheets at fair value measured on a recurring basis. There were no transfers of assets and liabilities that were recorded at fair value between the three-level fair value hierarchy during the periods reported.
In millions Level 1 (1)
Level 2 (2)
Level 3 (3)
Total
March 31, 2025
Assets:
Deferred compensation plan investments (4)
$ 3.8 $ — $ — $ 3.8
Total assets $ 3.8 $ — $ — $ 3.8
Liabilities:
Deferred compensation arrangement (4)
$ 15.3 $ — $ — $ 15.3
Total liabilities $ 15.3 $ — $ — $ 15.3
In millions Level 1 (1)
Level 2 (2)
Level 3 (3)
Total
December 31, 2024
Assets:
Deferred compensation plan investments (4)
$ 3.7 $ — $ — $ 3.7
Total assets $ 3.7 $ — $ — $ 3.7
Liabilities:
Deferred compensation arrangement (4)
$ 15.9 $ — $ — $ 15.9
Total liabilities $ 15.9 $ — $ — $ 15.9
______________
(1) Quoted prices in active markets for identical assets.
(2) Quoted prices for similar assets and liabilities in active markets.
(3) Significant unobservable inputs.
(4) Consists of a deferred compensation arrangement through which we hold various investment securities recognized on our condensed consolidated balance sheets. Both the asset and liability related to investment securities are recorded at fair value and are included within "Other assets" and "Other liabilities" on the condensed consolidated balance sheets, respectively. In addition to the investment securities, we also had company-owned life insurance related to the deferred compensation arrangement recorded at cash surrender value in "Other assets" of $ 16.3 million and $ 16.5 million at March 31, 2025 and December 31, 2024, respectively.
9
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Nonrecurring Fair Value Measurements
There were no nonrecurring fair value measurements on the condensed consolidated balance sheets during the periods ended March 31, 2025, and December 31, 2024.
Strategic Investments
Equity Method Investments
The aggregate carrying value of all strategic equity method investments totaled $ 15.3 million and $ 15.4 million at March 31, 2025 and December 31, 2024, respectively. As of March 31, 2025, we had approximately $ 5.2 million of unfunded commitments, associated with a venture capital fund investment accounted for under the equity method of accounting. We anticipate this will be paid over a period of 10 years, beginning from the fourth quarter of 2022.
There were no adjustments to the carrying value of equity method investments for impairment for the periods ended March 31, 2025 and December 31, 2024, respectively.
Measurement Alternative Investments
The aggregate carrying value of all measurement alternative investments where fair value is not readily determinable totaled $ 71.9 million at both March 31, 2025 and December 31, 2024. During the first quarter of 2024, the company identified a triggering event indicating that an investment being accounted for under the measurement alternative may be impaired. For the three months ended March 31, 2024, the company recognized an impairment of $ 4.8 million recorded in "Other (income) expense, net" on the condensed consolidated statements of operations. There were no adjustments to the carrying value of the measurement alternative method investments for impairment or observable price changes for the period ended March 31, 2025.
Restricted Investment
Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with our Performance Materials' Wickliffe, Kentucky manufacturing site at maturity. The trust, presented as Restricted investment on our condensed consolidated balance sheets, originally purchased long-term bonds that mature through 2026. The principal received at maturity of the bonds, along with interest income that is reinvested in the trust, is expected to be equal to or more than the $ 80.0 million finance lease obligation that is due in 2027. Because the provisions of the trust provide us the ability, and it is our intent, to hold the investments to maturity, the investments held by the trust are accounted for as held to maturity ("HTM"); therefore, they are held at their amortized cost. The investments held by the trust earn interest at the stated coupon rate of the invested bonds. Interest earned on the investments held by the trust is recognized and presented as interest income on our condensed consolidated statements of operations. As interest from the bonds is received and as bonds mature, any proceeds not reinvested are held in highly liquid securities and treated as restricted cash.
At March 31, 2025 and December 31, 2024, the carrying value of our restricted investment was $ 82.4 million and $ 81.6 million, net of an allowance for credit losses of $ 0.1 million and $ 0.2 million, and included restricted cash of $ 18.9 million and $ 18.2 million, respectively. The fair value at March 31, 2025 and December 31, 2024 was $ 81.3 million and $ 80.3 million, respectively, based on Level 1 inputs.
The following table shows the total amortized cost of our HTM debt securities by credit rating, excluding the allowance for credit losses and cash. The primary factor in our expected credit loss calculation is the composite bond rating. As the rating decreases, the risk present in holding the bond is inherently increased, leading to an increase in expected credit losses.
HTM Debt Securities
In millions AA+ AA- A A- BBB+ Total
March 31, 2025 $ 13.2 10.3 23.3 6.8 10.0 $ 63.6
December 31, 2024 $ 13.2 10.3 23.3 6.8 10.0 $ 63.6
Debt and Finance Lease Obligations
At March 31, 2025 and December 31, 2024, the carrying value of finance lease obligations was $ 99.7 million and $ 100.0 million, respectively, and the fair value was $ 102.0 million and $ 102.2 million, respectively. The fair value of our finance lease obligation associated with our Performance Materials' Wickliffe, Kentucky manufacturing site, is based on the
10
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
period-end quoted market prices for the obligation, using Level 2 inputs. The fair value of all other finance lease obligations approximates their carrying values.
The carrying value of our variable interest rate debt, excluding debt issuance fees and adjusted for our $ 200.0 million floating-to-fixed interest rate swap, was $ 547.3 million and $ 555.2 million as of March 31, 2025 and December 31, 2024, respectively. The carrying value of our variable rate debt is a reasonable estimate of the fair value.
At both March 31, 2025 and December 31, 2024, the carrying value of our fixed rate debt was $ 550.0 million, and the fair value was $ 513.2 million and $ 503.2 million, respectively, based on Level 2 inputs.
Note 5: Inventories, net
In millions March 31, 2025 December 31, 2024
Raw materials $ 78.5 $ 97.6
Production materials, stores, and supplies 25.5 25.0
Finished and in-process goods 206.6 186.2
Subtotal $ 310.6 $ 308.8
Less: LIFO reserve ( 65.2 ) ( 82.0 )
Inventories, net $ 245.4 $ 226.8
During the quarter ended March 31, 2025, inventory quantities carried on a LIFO basis, primarily in our Performance Chemicals reportable segment domestic inventory, were reduced which led to liquidations of LIFO inventory quantities. These planned reductions in inventory are not expected to be replaced by the end of the year and resulted in a pre-tax decrease of $ 2.9 million, recorded in "Cost of sales" on our condensed consolidated statement of operations.
Note 6: Property, Plant, and Equipment, net
In millions March 31, 2025 December 31, 2024
Machinery and equipment $ 1,310.9 $ 1,296.4
Buildings and leasehold improvements 229.1 224.3
Land and land improvements 26.2 26.2
Construction in progress 62.9 68.9
Total cost $ 1,629.1 $ 1,615.8
Less: accumulated depreciation (1)
( 973.3 ) ( 956.9 )
Property, plant, and equipment, net $ 655.8 $ 658.9
_______________
(1) As a result of the Performance Chemicals repositioning, as further described in Note 11, we accelerated the depreciation of certain property, plant and equipment assets. This resulted in zero and $ 31.6 million of additional expense for the three months ended March 31, 2025 and 2024 , respectively, which is included in "Restructuring and other (income) charges, net" within the condensed consolidated statements of operations.
11
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 7: Goodwill and Other Intangible Assets, net
Goodwill
Reporting Units
In millions Performance Materials Performance Chemicals Advanced Polymer Technologies Total
Goodwill $ 4.3 $ 349.1 $ 170.9 $ 524.3
Accumulated impairment losses — ( 349.1 ) — ( 349.1 )
Balance as of December 31, 2024
$ 4.3 $ — $ 170.9 $ 175.2
Foreign currency translation — — 5.5 5.5
Balance as of March 31, 2025
$ 4.3 $ — $ 176.4 $ 180.7
There were no events or circumstances indicating that goodwill might be impaired as of March 31, 2025.
Other Intangible Assets
In millions Customer contracts and relationships Brands (1)
Developed Technology Total
Gross Asset Value
December 31, 2024 $ 264.9 $ 91.4 $ 88.7 $ 445.0
Foreign currency translation 4.9 2.1 2.1 9.1
March 31, 2025 $ 269.8 $ 93.5 $ 90.8 $ 454.1
Accumulated Amortization
December 31, 2024 $ ( 88.4 ) $ ( 35.4 ) $ ( 42.4 ) $ ( 166.2 )
Amortization (2)
( 3.7 ) ( 1.4 ) ( 2.4 ) ( 7.5 )
Foreign currency translation ( 1.8 ) ( 0.7 ) ( 1.1 ) ( 3.6 )
March 31, 2025 $ ( 93.9 ) $ ( 37.5 ) $ ( 45.9 ) $ ( 177.3 )
Other intangibles, net $ 175.9 $ 56.0 $ 44.9 $ 276.8
_______________
(1) Represents trademarks, trade names, and know-how.
(2) As a result of the Performance Chemicals repositioning, as further described in Note 11, we accelerated the amortization of certain customer contract and relationship finite-lived intangible assets. This resulted in zero and $ 22.1 million of additional expense for the three months ended March 31, 2025 and 2024, respectively, which is included in "Restructuring and other (income) charges, net" within the condensed consolidated statements of operations.
Intangible assets subject to amortization were attributed to our business segments as follows:
In millions March 31, 2025 December 31, 2024
Performance Materials $ 1.2 $ 1.2
Performance Chemicals 99.7 102.5
Advanced Polymer Technologies 175.9 175.1
Other intangibles, net $ 276.8 $ 278.8
12
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
The amortization expense related to our intangible assets in the table above is shown in the table below.
Three Months Ended March 31,
In millions 2025 2024
Selling, general, and administrative expenses $ 7.5 $ 9.5
Restructuring and other (income) charges, net (1)
— 22.1
Total amortization expense $ 7.5 $ 31.6
_______________
(1) Amounts recorded to Restructuring and other (income) charges, net are not included within segment depreciation and amortization.
Based on the current carrying values of intangible assets, estimated pre-tax amortization expense for the next five years is as follows: $ 22.2 million for the remainder of 2025, 2026 - $ 29.0 million, 2027 - $ 29.0 million, 2028 - $ 29.0 million, and 2029 - $ 29.0 million. The estimated pre-tax amortization expense may fluctuate due to changes in foreign currency exchange rates.
Note 8: Financial Instruments and Risk Management
Cash Flow Hedges
Foreign Currency Exchange Risk Management
As of March 31, 2025, there were $ 4.7 million open foreign currency derivative contracts. The fair value of the designated foreign currency hedge contracts was a net asset (liability) of $( 0.1 ) million and $ 0.1 million at March 31, 2025 and December 31, 2024, respectively.
Commodity Price Risk Management
As of March 31, 2025, we had 1.8 million mmBTUS (millions of British Thermal Units) in open natural gas derivative contracts, designated as cash flow hedges. As of March 31, 2025, open natural gas derivative contracts hedge a portion of forecasted transactions until June 2026. The fair value of the open natural gas derivative contracts was a net asset (liability) of $ 1.0 million and $ 0.3 million as of March 31, 2025 and December 31, 2024, respectively.
Interest Rate Risk Management
During the third quarter of 2024, we entered into a floating-to-fixed interest rate swap with a notional amount of $ 200.0 million to manage the variability of cash flows in the interest rate payments associated with our existing Secured Overnight Financing Rate ("SOFR") based interest payments, effectively converting $ 200.0 million of our floating rate debt to a fixed rate. In accordance with the terms of this instrument, we receive floating rate interest payments based upon one-month U.S. dollar SOFR and in return are obligated to pay interest at a fixed rate of 3.84 percent until August 2026. The fair value of the interest rate swap was an asset (liability) of $( 0.1 ) million and $ 0.6 million at March 31, 2025 and December 31, 2024, respectively.
Effect of Cash Flow Hedge Accounting on AOCI
In millions Amount of Gain (Loss) Recognized in AOCI Amount of Gain (Loss) Reclassified from AOCI into Net income (loss) Location of Gain (Loss) Reclassified from AOCI in Net income (loss)
Three Months Ended March 31,
2025 2024 2025 2024
Cash flow hedging derivatives
Currency exchange contracts $ ( 0.1 ) $ — $ — $ — Net sales
Natural gas contracts 1.0 ( 0.4 ) ( 0.2 ) ( 0.7 ) Cost of sales
Interest rate swap contracts ( 0.8 ) — — — Interest expense, net
Total $ 0.1 $ ( 0.4 ) $ ( 0.2 ) $ ( 0.7 )
13
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Within the next twelve months, we expect to reclassify $ 1.3 million of net gains from AOCI to income, before taxes.
Fair Value Measurements
The following information is presented for derivative assets and liabilities that are recorded in the condensed consolidated balance sheets at fair value measured on a recurring basis. There were no transfers of assets and liabilities that are recorded at fair value between Level 1 and Level 2 during the periods reported. There were no nonrecurring fair value measurements related to derivative assets and liabilities on the condensed consolidated balance sheets as of March 31, 2025, or December 31, 2024.
March 31, 2025
In millions Level 1 (1)
Level 2 (2)
Level 3 (3)
Total
Assets:
Natural gas contracts (4)
$ — $ 1.2 $ — $ 1.2
Currency exchange contracts (4)
— 0.1 — 0.1
Total assets $ — $ 1.3 $ — $ 1.3
Liabilities:
Natural gas contracts (6)
$ — $ 0.2 $ — $ 0.2
Currency exchange contracts (6)
— 0.2 — 0.2
Interest rate swap contracts (7)
— 0.1 — 0.1
Total liabilities $ — $ 0.5 $ — $ 0.5
December 31, 2024
In millions Level 1 (1)
Level 2 (2)
Level 3 (3)
Total
Assets:
Natural gas contracts (4)
$ — $ 0.4 $ — $ 0.4
Currency exchange contracts (4)
— 0.2 — 0.2
Interest rate swap contracts (5)
— 0.6 — 0.6
Total assets $ — $ 1.2 $ — $ 1.2
Liabilities:
Natural gas contracts (6)
$ — $ 0.1 $ — $ 0.1
Currency exchange contracts (6)
— 0.1 — 0.1
Total liabilities $ — $ 0.2 $ — $ 0.2
__________
(1) Quoted prices in active markets for identical assets.
(2) Quoted prices for similar assets and liabilities in active markets.
(3) Significant unobservable inputs.
(4) Included within "Prepaid and other current assets" on the condensed consolidated balance sheets.
(5) Included within "Other assets" on the condensed consolidated balance sheets.
(6) Included within "Accrued expenses" on the condensed consolidated balance sheets.
(7) Included within "Other liabilities" on the condensed consolidated balance sheets.
14
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 9: Debt, including Finance Lease Obligations
Current and long-term debt including finance lease obligations consisted of the following:
In millions, except percentages March 31, 2025 December 31, 2024
Revolving Credit Facility and other lines of credit (1)(2)
$ 688.0 $ 695.0
3.88 % Senior Notes due 2028
550.0 550.0
Finance lease obligations (3)
99.7 100.0
Accounts receivable securitization (4)
57.3 58.3
Other notes payable 2.0 1.9
Total debt including finance lease obligations $ 1,397.0 $ 1,405.2
Less: debt issuance costs 4.0 4.2
Total debt including finance lease obligations, net of debt issuance costs $ 1,393.0 $ 1,401.0
Less: debt maturing within one year (5)
60.4 61.3
Long-term debt including finance lease obligations $ 1,332.6 $ 1,339.7
______________
(1) Letters of credit outstanding under the revolving credit facility were $ 2.6 million and $ 2.6 million and available funds under the facility were $ 309.4 million and $ 302.4 million at March 31, 2025 and December 31, 2024, respectively.
(2) The effective interest rate associated with our revolving credit facility, exclusive of any floating-to-fixed interest rate instrument, was 6.54 percent and 7.48 percent for the period ended March 31, 2025 and December 31, 2024, respectively.
(3) As of March 31, 2025 and December 31, 2024, $ 80.0 million of the finance lease obligation upon maturity will be settled utilizing liquid assets that have been placed into a trust established strictly for this purpose. The trust is presented as Restricted investments on the condensed consolidated balance sheets in the amount of $ 82.4 million and $ 81.6 million as of March 31, 2025 and December 31, 2024, respectively. Refer to Note 4, under the section: Restricted Investment , for more information.
(4) The effective interest rate associated with our accounts receivable securitization program was 5.82 percent and 6.65 percent for the period ended March 31, 2025 and December 31, 2024, respectively.
(5) Debt maturing within one year is included in "Notes payable and current maturities of long-term debt" on the condensed consolidated balance sheets.
Debt Covenants
Our indenture contains certain customary covenants (including covenants limiting Ingevity's and its restricted subsidiaries’ ability to grant or permit liens on certain property securing debt, declare or pay dividends, make distributions on or repurchase or redeem capital stock, make investments in unrestricted subsidiaries, engage in sale and lease-back transactions, and engage in a consolidation or merger, or sell, transfer or otherwise dispose of all or substantially all of the assets of Ingevity and our restricted subsidiaries, taken as a whole) and events of default (subject in certain cases to customary exceptions, as well as grace and cure periods). The occurrence of an event of default under the 2028 Senior Notes could result in the acceleration of the notes of such series and could cause a cross-default resulting in the acceleration of other indebtedness of Ingevity and its subsidiaries. We were in compliance with all covenants under the indenture as of March 31, 2025.
The credit agreement governing our revolving credit facility contains customary default provisions, including defaults for non-payment, breach of representations and warranties, insolvency, non-compliance with covenants and cross-defaults to other material indebtedness. The occurrence of an uncured event of default under the credit agreement could result in all loans and other obligations becoming immediately due and payable and our revolving credit facility being terminated. The credit agreement also contains certain customary covenants, including financial covenants. The revolving credit facility financial covenants require Ingevity to maintain on a consolidated basis a maximum total net leverage ratio of 4.0 to 1.0 (which may be increased to 4.5 to 1.0 under certain circumstances) and a minimum interest coverage ratio of 3.0 to 1.0. As calculated per the credit agreement, our net leverage for the four consecutive quarters ended March 31, 2025 was 3.2 , and our actual interest coverage for the four consecutive quarters ended March 31, 2025 was 4.7 . We were in compliance with all covenants under the credit agreement at March 31, 2025.
15
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 10: Equity
Common Stock
In millions, shares in thousands Shares Amount Additional paid in capital Retained earnings Accumulated
other
comprehensive
income (loss) Treasury stock Total Equity
Balance at December 31, 2024 43,630 $ 0.4 $ 176.8 $ 572.0 $ ( 41.4 ) $ ( 512.6 ) $ 195.2
Net income (loss) — — — 20.5 — — 20.5
Other comprehensive income (loss) — — — — 17.4 — 17.4
Common stock issued 155 — — — — — —
Tax payments related to vested restricted stock units — — — — — ( 2.6 ) ( 2.6 )
Share-based compensation plans — — 4.1 — — — 4.1
Balance at March 31, 2025 43,785 $ 0.4 $ 180.9 $ 592.5 $ ( 24.0 ) $ ( 515.2 ) $ 234.6
Common Stock
In millions, shares in thousands Shares Amount Additional paid in capital Retained earnings Accumulated
other
comprehensive
income (loss) Treasury stock Total Equity
Balance at December 31, 2023 43,447 $ 0.4 $ 164.9 $ 1,002.3 $ ( 26.7 ) $ ( 509.5 ) $ 631.4
Net income (loss) — — — ( 56.0 ) — — ( 56.0 )
Other comprehensive income (loss) — — — — ( 8.9 ) — ( 8.9 )
Common stock issued 138 — — — — — —
Tax payments related to vested restricted stock units — — — — — ( 2.6 ) ( 2.6 )
Share-based compensation plans — — 4.3 — — — 4.3
Balance at March 31, 2024 43,585 $ 0.4 $ 169.2 $ 946.3 $ ( 35.6 ) $ ( 512.1 ) $ 568.2
16
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Accumulated other comprehensive income (loss)
Three Months Ended March 31,
In millions 2025 2024
Foreign currency translation
Beginning balance $ ( 44.4 ) $ ( 25.6 )
Net gains (losses) on foreign currency translation 17.2 ( 9.1 )
Other comprehensive income (loss), net of tax 17.2 ( 9.1 )
Ending balance $ ( 27.2 ) $ ( 34.7 )
Derivative instruments
Beginning balance $ 0.5 $ ( 1.6 )
Gains (losses) on derivative instruments 0.1 ( 0.4 )
Less: tax provision (benefit) — ( 0.1 )
Net gains (losses) on derivative instruments 0.1 ( 0.3 )
(Gains) losses reclassified to net income 0.2 0.7
Less: tax (provision) benefit 0.1 0.2
Net (gains) losses reclassified to net income 0.1 0.5
Other comprehensive income (loss), net of tax 0.2 0.2
Ending balance $ 0.7 $ ( 1.4 )
Pension and other postretirement benefits
Beginning balance $ 2.5 $ 0.5
Other comprehensive income (loss), net of tax — —
Ending balance $ 2.5 $ 0.5
Total AOCI ending balance at March 31 $ ( 24.0 ) $ ( 35.6 )
Reclassifications of accumulated other comprehensive income (loss)
Three Months Ended March 31,
In millions 2025 2024
Derivative instruments
Natural gas contracts (1)
$ ( 0.2 ) $ ( 0.7 )
Total before tax ( 0.2 ) ( 0.7 )
(Provision) benefit for income taxes 0.1 0.2
Amount included in net income (loss) $ ( 0.1 ) $ ( 0.5 )
______________
(1) Included within "Cost of sales" on the condensed consolidated statements of operations.
17
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Share Repurchases
On July 25, 2022, our Board of Directors authorized the repurchase of up to $ 500.0 million of our common stock (the "2022 Authorization"), and rescinded the prior outstanding repurchase authorization with respect to the shares that remained unused under the prior authorization. Shares under the 2022 Authorization may be purchased through open market or privately negotiated transactions at the discretion of management based on its evaluation of market prevailing conditions and other factors, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
During the three months ended March 31, 2025 and 2024, we repurchased no common stock. At March 31, 2025, $ 353.4 million remained unused under the 2022 Authorization.
Note 11: Restructuring and Other (Income) Charges, net
Detail on the restructuring charges and other (income) charges, net, is provided below.
Three Months Ended March 31,
In millions 2025 2024
Restructuring charges $ 12.3 $ 62.3
Other (income) charges, net — 0.5
Total Restructuring and other (income) charges, net $ 12.3 $ 62.8
Restructuring Charges
In millions Severance and other employee-related costs Other charges (income) (1)
Asset disposal charges (2)
Total
Performance Chemicals repositioning $ — $ 11.2 $ ( 0.1 ) $ 11.1
Other (3)
0.8 0.3 0.1 1.2
Three Months Ended March 31, 2025 $ 0.8 $ 11.5 $ — $ 12.3
Performance Chemicals repositioning $ 2.1 $ 5.2 $ 55.0 $ 62.3
Three Months Ended March 31, 2024 $ 2.1 $ 5.2 $ 55.0 $ 62.3
_______________
(1) Primarily represents costs associated with contract terminations, plant and equipment decommissioning charges and other miscellaneous exit costs.
(2) Primarily represents property, plant and equipment and finite-lived intangible asset write-downs, accelerated depreciation and amortization, and impairment charges on certain assets, which were or are to be disposed of or abandoned. Also included, to the extent incurred, the acceleration effect of re-estimating settlement dates and revised cost estimates associated with asset retirement obligations related to asset disposal charges that are included within restructuring charges.
(3) During 2024, we took further steps to streamline our cost structure and improve profitability, resulting in additional restructuring charges for the quarter ended March 31, 2025 of $ 1.2 million, including $ 0.1 million in asset disposal charges, $ 0.8 million in severance and other employee-related costs, and $ 0.3 million in other charges.
Performance Chemicals Repositioning
On November 1, 2023, we announced a number of strategic actions designed to reposition our Performance Chemicals reportable segment to improve profitability and reduce the cyclicality of the company as a whole. These actions increased our focus on growing our most profitable Performance Chemicals product lines, such as road technologies, and diversifying our raw material stream to non-CTO based fatty acids. The repositioning focused on reducing exposure to lower margin end-use markets of our industrial specialties product line, such as adhesives, publication inks, and oilfield, representing approximately 45 percent of our industrial specialties product line historical annualized net sales. The repositioning included the closure of the Performance Chemicals CTO refinery and manufacturing plant located in DeRidder, Louisiana (the “DeRidder Plant”), including the polyol production assets associated with the Advanced Polymer Technologies ("APT") reportable segment. All production at the DeRidder Plant ceased in the first quarter of 2024. The Performance Chemicals repositioning initiative included additional corporate and business cost reduction actions executed in November 2023.
18
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Additionally, in July 2024, we announced plans to transition the refining of oleo-based products manufactured for the Performance Chemicals reportable segment from our Crossett, Arkansas manufacturing plant (the “Crossett Facility”) to our North Charleston, South Carolina manufacturing plant. This action included the closure of the Crossett Facility, as well as additional corporate and business cost reduction actions. We ceased production at the Crossett Facility in the third quarter of 2024.
The actions referenced above, when combined with other targeted workforce reduction initiatives during 2024 and 2023, resulted in the reduction of Ingevity's global workforce by 23 percent. Specific to Performance Chemicals, the reduction represented approximately 40 percent of the reportable segment's workforce.
Expected Charges
We expect to incur aggregate charges of approximately $ 360 million, excluding the CTO resale activity as described below, associated with the Performance Chemicals repositioning, consisting of approximately $ 250 million in asset-related charges, approximately $ 25 million in severance and other employee-related costs, and approximately $ 85 million in other restructuring costs, including decommissioning, dismantling and removal charges, and contract termination costs. Through March 31, 2025, we have incurred $ 322.9 million associated with these actions, including $ 244.7 million of non-cash asset-related charges, excluding $ 7.4 million related to an asset retirement obligation ("ARO"), and $ 78.2 million of charges to be settled in cash, which include the aforementioned ARO. As of March 31, 2025, $ 65.0 million of the charges to be settled in cash have been paid and all non-cash charges have been incurred. In total, we expect approximately $ 110 million of cash charges, including approximately $ 25 -$ 30 million during 2025.
The charges we currently expect to incur in connection with these actions are subject to a number of assumptions and risks, and actual results may differ materially. We may also incur other material charges not currently contemplated due to events that may occur as a result of, or in connection with, these actions.
Inventory Charges
The company believes the collective actions of workforce, operational, and regional business exits will hinder our ability to dispose of the associated inventory on hand. As a result, we recorded zero and $ 2.5 million of non-cash, lower of cost or market, inventory charges during the three months ended March 31, 2025, and 2024, respectively, to adjust the carrying value of the impacted inventory to what we expect to realize upon disposal, less disposal costs. These inventory charges are recorded to "Cost of sales" on the condensed consolidated statements of operations. Since these inventory charges are directly attributable to the Performance Chemicals repositioning, that is, they do not represent normal, recurring expenses necessary to operate our business, we have excluded such impact from the financial results of our Performance Chemicals reportable segment. Refer to Note 14 for more information.
CTO Resale Activity
The DeRidder Plant closure, and the corresponding reduction in CTO refining capacity, significantly reduced our CTO volume requirements. However, we were obligated, under an existing CTO supply contract, to purchase CTO volumes through 2025 at amounts in excess of the CTO volumes needed to support our business operations. To manage this excess inventory, we sold CTO volumes (herein referred to as "CTO resales") in the open market. For the three months ended March 31, 2025 and 2024, we have incurred zero and $ 26.5 million, respectively, of CTO resale losses, which are recorded as "Other (income) expense, net" on the condensed consolidated statements of operations.
On July 1, 2024, the CTO supply contract that resulted in these excess CTO volumes was terminated. As consideration for the termination of the CTO supply contract, we made cash payments totaling $ 100.0 million during 2024. The charge was recorded within "Other (income) expense, net" on the condensed consolidated statements of operations for the year ended December 31, 2024. As a result of the termination, the purchases under the CTO supply contract ended effective June 30, 2024. The CTO resale activity described above ended in 2024 and no excess CTO volumes were on hand at March 31, 2025.
Other (income) charges, net
North Charleston plant transition
Our North Charleston, South Carolina Performance Chemicals manufacturing plant has historically been co-located with a WestRock Company (“WestRock”) paper mill. In May 2023, WestRock announced that it would permanently cease
19
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
operating its North Charleston paper mill by August 31, 2023 and notified us that it was terminating the shared services in accordance with our operating agreement. WestRock ceased production at their North Charleston paper mill in June 2023. During 2023, we executed a transition plan to separate certain critical operating services WestRock had historically provided to us such as steam, water and wastewater treatment. During the three months ended March 31, 2025 and 2024, we incurred charges of zero and $ 0.5 million, respectively.
Restructuring and Other (Income) Charges, net Reserves
The following table shows a roll forward of restructuring reserves that will result in cash spending, the majority of which relate to the Performance Chemicals repositioning.
Balance at Change in Cash Balance at
In millions 12/31/2024 (1)
Reserve (2)
Payments Other (3)
3/31/2025 (1)
Severance and other employee-related costs $ 4.2 0.8 ( 2.6 ) — $ 2.4
Other charges (income) 0.9 11.5 ( 9.0 ) — 3.4
Restructuring 5.1 12.3 ( 11.6 ) — 5.8
Other (income) charges, net — — — — —
Restructuring and Other (income) charges, net reserves $ 5.1 12.3 ( 11.6 ) — $ 5.8
_______________
(1) Included in "Accrued expenses" on the condensed consolidated balance sheets.
(2) Includes severance and other employee-related costs, exited leases, CTO supply contract terminations and other miscellaneous exit costs. Any asset write-downs including accelerated depreciation and impairment charges are not included in the above table.
(3) Primarily foreign currency translation adjustments.
Note 12: Income Taxes
The effective tax rates, including discrete items, were as follows:
Three Months Ended March 31,
2025 2024
Effective tax rate 23.5 % 22.1 %
We determine our interim tax provision using an Estimated Annual Effective Tax Rate methodology (“EAETR”). The EAETR is applied to the year-to-date ordinary income, exclusive of discrete items. The tax effects of discrete items are then included to arrive at the total reported interim tax provision.
The determination of the EAETR is based upon a number of estimates, including the estimated annual pre-tax ordinary income in each tax jurisdiction in which we operate. As our projections of ordinary income change throughout the year, the EAETR will change period-to-period. The tax effects of discrete items are recognized in the tax provision in the period they occur. Depending on various factors, such as the item’s significance in relation to total income and the rate of tax applicable in the jurisdiction to which it relates, discrete items in any quarter may materially impact the reported effective tax rate. As a global enterprise, our tax expense may be impacted by changes in tax rates or laws, the finalization of tax audits and reviews, as well as other factors. As such, there may be significant volatility in interim tax provisions.
20
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
The below table provides a reconciliation between our reported effective tax rates and the EAETR.
Three Months Ended March 31,
2025 2024
In millions, except percentages Before tax Tax Effective tax rate % impact Before tax Tax Effective tax rate % impact
Consolidated operations $ 26.8 $ 6.3 23.5 % $ ( 71.9 ) $ ( 15.9 ) 22.1 %
Discrete items:
Restructuring and other (income) charges, net (1)
12.3 2.9 64.8 15.1
(Gain) loss on strategic investments (2)
— — 4.8 1.1
Proxy contest charges (3)
7.9 1.8 — —
Other tax only discrete items — ( 0.4 ) — ( 0.9 )
Total discrete items 20.2 4.3 69.6 15.3
Consolidated operations, before discrete items $ 47.0 $ 10.6 $ ( 2.3 ) $ ( 0.6 )
EAETR (4)
22.6 % 24.2 %
_______________
(1) See Note 11 for further information. For the three months ended March 31, 2024, the charge includes $ 2.5 million of lower of cost or market charges associated with the Performance Chemicals repositioning. Amounts are included in "Cost of sales" on the condensed consolidated statements of operations.
(2) See Note 4 for further information.
(3) See Note 14 for further information.
(4) Decrease in EAETR for the three months ended March 31, 2025, as compared to March 31, 2024, is due to an overall change in the mix of forecasted earnings in various tax jurisdictions with varying rates, most notably in the U.S. Additionally, the foreign-derived intangible income deduction, which was significantly decreased in 2024 due to reductions in taxable income in the U.S., is driving notable benefit to the EAETR in 2025. The EAETR tax percentage shown for three months ended March 31, 2024 may not precisely recalculate due to rounding.
At March 31, 2025 and December 31, 2024, we had deferred tax assets of $ 11.6 million and $ 11.0 million, respectively, resulting from certain historical net operating losses from our Brazil and China operations and U.S. state tax credits for which a valuation allowance has been established. The ultimate realization of these deferred tax assets depends on the generation of future taxable income during the periods in which these net operating losses and tax credits are available to be used. In evaluating the realizability of these deferred tax assets, we consider projected future taxable income and tax planning strategies in making our assessment. As of March 31, 2025, we cannot objectively assert that these deferred tax assets are more likely than not to be realized and therefore we have maintained a valuation allowance. We intend to continue maintaining a valuation allowance on these deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances. A release of all or a portion of the valuation allowance could be possible if we determine that sufficient positive evidence becomes available to allow us to reach a conclusion that the valuation allowance will no longer be needed. A release of the valuation allowance would result in the recognition of certain deferred tax assets and a reduction to income tax expense for the period the release is recorded. However, the exact timing and amount of the valuation allowance release are subject to change based on the level of profitability that we are able to actually achieve.
Pillar Two, released by the Organisation for Economic Cooperation and Development (OECD), went into effect on January 1, 2024. Pillar Two’s intent is to create a 15% global minimum tax for all jurisdictions in which multinational enterprises operate. To date, fourteen of our reporting jurisdictions have enacted final legislation adopting Pillar Two. While we do not anticipate that this legislation will have a material impact on our tax provision or effective tax rate, we continue to monitor evolving tax legislation in the jurisdictions in which we operate. No tax impacts of Pillar Two were recorded for the quarter ended March 31, 2025.
21
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 13: Commitments and Contingencies
Legal Proceedings
On July 19, 2018, we filed suit against BASF Corporation (“BASF”) in the United States District Court for the District of Delaware (the “Delaware Proceeding”) alleging BASF infringed Ingevity’s patent covering canister systems used in the control of automotive gasoline vapor emissions (U.S. Patent No. RE38,844) (the “844 Patent”). On February 14, 2019, BASF asserted counterclaims against us in the Delaware Proceeding, alleging two claims for violations of U.S. antitrust law (one for exclusive dealing and the other for tying) as well as a claim for tortious interference with an alleged prospective business relationship between BASF and a BASF customer (the “BASF Counterclaims”). The BASF Counterclaims relate to our enforcement of the 844 Patent and our entry into several supply agreements with customers of our fuel vapor canister honeycombs. The U.S. District Court dismissed our patent infringement claims on November 18, 2020, and the case proceeded to trial on the BASF Counterclaims in September 2021.
On September 15, 2021, a jury in the Delaware Proceeding issued a verdict in favor of BASF on the BASF Counterclaims and awarded BASF damages of approximately $ 28.3 million, which trebled under U.S. antitrust law to approximately $ 85.0 million. On May 18, 2023, the court in the Delaware Proceeding entered judgment on the jury’s verdict, which commenced the post-trial briefing stage. On February 13, 2024, the court in the Delaware Proceeding denied BASF’s motion for pre-judgment interest on its tortious interference claim as well as our motion seeking judgment as a matter of law, or a new trial in the alternative. In addition, BASF has indicated it will seek attorneys’ fees and costs in amounts that they will allege and have to demonstrate at a future date. Unless the judgment is set aside, BASF will be entitled to post-judgment interest pursuant to the rate provided under federal law.
We disagree with the verdict, including the court’s application of the law and entry of judgment. Therefore, on March 13, 2024, we appealed the verdict as well as the U.S. District Court’s November 2020 dismissal of our patent infringement claims against BASF. Ingevity believes in the strength of its intellectual property and the merits of its position and intends to pursue all legal relief available to challenge these outcomes in the Delaware Proceeding. Final resolution of these appeals could take up to 15 months.
As of March 31, 2025, nothing has occurred in the post-trial proceedings to warrant any change to our conclusions as disclosed within our Annual Report on Form 10-K for the year ended December 31, 2024. The full amount of the trebled jury's verdict, $ 85.0 million, is accrued in "Other liabilities" on the condensed consolidated balance sheets as of March 31, 2025 and the charge was included within "Other (income) expense, net" on the condensed consolidated statements of operations for the year ended December 31, 2021. In addition, as a result of the judgment being entered on May 18, 2023, we have started accruing for post-judgment interest at the legally mandated interest rate. As of March 31, 2025 and December 31, 2024, the total amount accrued, inclusive of post-judgement interest, was $ 92.4 million and $ 91.4 million, respectively. The amount of any liability we may ultimately incur could be more or less than the amount accrued.
22
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 14: Segment Information
Ingevity’s operating segments are (i) Performance Materials ("PM"), (ii) Performance Chemicals ("PC"), and (iii) Advanced Polymer Technologies ("APT"). Our operating segments were determined based upon the nature of the products produced, the nature of the production process, the type of customer for the products, the similarity of economic characteristics, and the manner in which management reviews results. Segment EBITDA is the primary measure used by the chief operating decision maker ("CODM"), the CEO and President of Ingevity, to evaluate the performance of and allocate resources among our operating segments. The CODM utilizes Segment EBITDA for each operating segment in the annual budgeting and forecasting process. Segment EBITDA enables the CODM to compare each business and make informed and consistent resource allocation decisions.
Three Months Ended March 31,
In millions 2025 2024
Segment EBITDA (1)(2)
Performance Materials $ 79.1 $ 78.0
Performance Chemicals ( 0.3 ) ( 10.6 )
Advanced Polymer Technologies 12.5 9.5
Total Segment EBITDA (1)(2)
$ 91.3 $ 76.9
Interest expense, net ( 19.4 ) ( 22.3 )
(Provision) benefit for income taxes ( 6.3 ) 15.9
Depreciation and amortization ( 24.9 ) ( 29.6 )
Restructuring and other income (charges), net (3)
( 12.3 ) ( 62.8 )
Acquisition and other-related income (costs), net (4)
— ( 0.3 )
Inventory charges (5)
— ( 2.5 )
Loss on CTO resales (6)
— ( 26.5 )
Gain (loss) on strategic investments (7)
— ( 4.8 )
Proxy contest charges (8)
( 7.9 ) —
Net income (loss) $ 20.5 $ ( 56.0 )
_______________
(1) Segment EBITDA is defined as segment net sales less segment operating expenses (segment operating expenses consist of costs of sales, selling, general and administrative expenses, research and technical expenses, other (income) expense, net, excluding depreciation and amortization). We have excluded the following items from segment EBITDA: interest expense associated with corporate debt facilities, interest income, income taxes, depreciation, amortization, restructuring and other income (charges), net, inventory lower of cost or market charges associated with restructuring actions, goodwill impairment charges, acquisition and other-related income (costs), gain (loss) on sale of strategic investments, loss on CTO resales, CTO supply contract termination charges, proxy contest charges, and pension and postretirement settlement and curtailment income (charges), net.
23
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
(2) Segment expenses included within the primary measure used by our CODM are included within the below table.
Three Months Ended March 31,
2025 2024
In millions, except per share data PM PC APT PM PC APT
Net sales (i)
$ 146.8 $ 95.0 $ 42.2 $ 145.1 $ 147.0 $ 48.0
Less:
Cost of sales (ii) (iii)
54.4 77.4 23.6 52.1 135.9 32.4
Selling, general, and administrative expenses (ii) (iv)
16.4 18.8 5.9 15.0 21.1 5.8
Other (income) expense, net (ii) (v)
( 3.1 ) ( 0.9 ) 0.2 — 0.6 0.3
Segment EBITDA $ 79.1 $ ( 0.3 ) $ 12.5 $ 78.0 $ ( 10.6 ) $ 9.5
_______________
(i) Relates to external customers only. Refer to Note 3 for a reconciliation to consolidated Net sales.
(ii) Excludes Depreciation and amortization.
(iii) Inventory charges representing lower of cost or market charges associated with the Performance Chemicals repositioning and restructuring actions were not allocated in the measurement of Performance Chemicals reportable segment profitability used by our CODM. Amounts are included in Cost of sales on the condensed consolidated statements of operations.
(iv) Includes Research and technical expenses.
(v) We have excluded the following items from Other (income) expense, net: gain (loss) on sale of strategic investments, loss on CTO resales, CTO supply contract termination charges, proxy contest charges, depreciation, and amortization.
(3) The table below provides an allocation of these charges between our three reportable segments to provide investors, potential investors, securities analysts and others with the information, should they choose, to apply such (income) charges to each respective reportable segment for which the charges relate.
Three Months Ended March 31,
In millions 2025 2024
Performance Materials $ — $ 0.1
Performance Chemicals 11.7 62.8
Advanced Polymer Technologies 0.6 ( 0.1 )
Restructuring and other (income) charges, net $ 12.3 $ 62.8
(4) Charges represent (gains) losses incurred to complete and integrate acquisitions and other strategic investments. Charges may include the expensing of the inventory fair value step-up resulting from the application of purchase accounting for acquisitions and certain legal and professional fees associated with the completion of acquisitions and strategic investments. For the three months ended March 31, 2024, charges relate to the Performance Chemicals reportable segment.
(5) For the three months ended March 31, 2024, inventory charges represent lower of cost or market charges associated with the Performance Chemicals repositioning. These charges were not allocated in the measurement of Performance Chemicals reportable segment profitability used by our CODM. Amounts are included in "Cost of sales" on the condensed consolidated statements of operations.
(6) For the three months ended March 31, 2024, charges relate to the Performance Chemicals reportable segment. Refer to Note 11 for more information.
(7) We exclude gains and losses from strategic investments from our segment results, as well as our non-GAAP financial measures, because we do not consider such gains or losses to be directly associated with the operational performance of the segment. We believe that the inclusion of such gains or losses would impair the factors and trends affecting the historical financial performance of our reportable segments. We continue to include undistributed earnings or loss, distributions, amortization or accretion of basis differences, and other-than-temporary impairments for equity method investments that we believe are directly attributable to the operational performance of such investments, in our reportable segment results. Refer to Note 4, under the section: Strategic Investments , for more information.
Three Months Ended March 31,
In millions 2025 2024
Performance Materials $ — $ —
Performance Chemicals — 4.8
Advanced Polymer Technologies — —
(Gain) loss on strategic investments $ — $ 4.8
24
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
(8) Charges represent legal and other professional service fees as well as incremental proxy solicitation costs related to a proxy contest.
Depreciation and amortization Three Months Ended March 31,
In millions 2025 2024
Performance Materials $ 9.9 $ 9.6
Performance Chemicals 7.3 12.4
Advanced Polymer Technologies 7.7 7.6
Total depreciation and amortization $ 24.9 $ 29.6
Capital expenditures Three Months Ended March 31,
In millions 2025 2024
Performance Materials $ 5.1 $ 7.3
Performance Chemicals 1.2 6.2
Advanced Polymer Technologies 3.7 3.1
Total capital expenditures $ 10.0 $ 16.6
Total assets
In millions March 31, 2025 December 31, 2024
Performance Materials $ 850.9 $ 824.3
Performance Chemicals
556.2 567.1
Advanced Polymer Technologies 587.7 568.2
Total segment assets (1)
$ 1,994.8 $ 1,959.6
Corporate and other 61.3 63.0
Total assets $ 2,056.1 $ 2,022.6
_______________
(1) Segment assets exclude assets not specifically managed as part of one specific segment herein referred to as "Corporate and other."
Note 15: Earnings (Loss) per Share
Three Months Ended March 31,
In millions (except share and per share data) 2025 2024
Net income (loss) $ 20.5 $ ( 56.0 )
Basic and Diluted earnings (loss) per share
Basic earnings (loss) per share $ 0.56 $ ( 1.54 )
Diluted earnings (loss) per share 0.56 ( 1.54 )
Shares (in thousands)
Weighted average number of common shares outstanding - Basic 36,382 36,264
Weighted average additional shares assuming conversion of potential common shares 281 —
Shares - diluted basis (1)
36,663 36,264
_______________
(1) For the three months ended March 31, 2024, all potentially dilutive common shares were excluded from the calculation of diluted earnings (loss) per share as we had a net loss for the period.
25
INGEVITY CORPORATION
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
The following average number of potential common shares were antidilutive, and therefore, were not included in the diluted earnings per share calculation:
Three Months Ended March 31,
In thousands 2025 2024
Average number of potential common shares - antidilutive 275 304
26
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.